Compare CRESY & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | LBRX |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | Argentina | United States |
| Employees | 2889 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.2M | 602.6M |
| IPO Year | N/A | N/A |
| Metric | CRESY | LBRX |
|---|---|---|
| Price | $12.11 | $23.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | ★ 266.7K | 199.6K |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | ★ 7.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.39 | $13.40 |
| 52 Week High | $14.21 | $27.55 |
| Indicator | CRESY | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 50.31 |
| Support Level | $11.85 | $22.34 |
| Resistance Level | $12.21 | $24.95 |
| Average True Range (ATR) | 0.51 | 1.35 |
| MACD | 0.12 | -0.12 |
| Stochastic Oscillator | 59.27 | 31.16 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.